Results 1 to 2 of 2

Thread: InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

  1. #1

    InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

    InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011
    Published on August 11, 2011 at 7:53 AM · No Comments

    InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update. Highlights of the second quarter of 2011 and recent weeks include:

    Submitting an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) to begin a pilot study with the Company's proprietary biopolymer scaffolding device in acute SCI

    Management Commentary

    "We made important progress in recent months in our goal to provide effective therapies to prevent and treat spinal cord injuries, most notably filing an IDE for our biopolymer scaffolding device," commented Frank Reynolds, Chief Executive Officer of InVivo Therapeutics. "The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury. This is the first of several products we are advancing toward human clinical testing, and our scaffolding device will address a poorly served medical condition as most treatments are ineffective for the 12,000 Americans each year who suffer an acute spinal cord injury."


  2. #2
    From "Zacks" in July this rosy prediction even as the stock has traded down from above $4 to .78
    We think the initial focus will be on the acute market, with greater penetration coming as InVivo demonstrates utility with combination therapy, the Hydrogel, or with stem cells (hNSC). Given the significant unmet medical need and the lack of existing treatment options, we envision a price almost similar to an Orphan Drug. We think that $60,000 per implant is reasonable for the BSD alone, with InVivo maintaining the ability to raise the price to $75,000 and $100,000 as the Hydrogel and BSD + cells comes to market. Under this scenario, with just 10% market penetration, InVivo’s device could have billion-dollar potential. We think once the next-generation products are approved, market penetration can soar to 20%, meaning peak sales for the BSD + cell is in the area of $2.5 billion.

Similar Threads

  1. Replies: 1
    Last Post: 05-17-2011, 08:45 AM
  2. Replies: 3
    Last Post: 05-05-2011, 09:28 AM
  3. Replies: 0
    Last Post: 05-06-2009, 03:43 PM
  4. about InVivo Therapeutics co.
    By manouli in forum Cure
    Replies: 0
    Last Post: 10-31-2008, 12:15 AM
  5. Replies: 1
    Last Post: 08-16-2002, 09:20 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts